Halozyme Therapeutics (HALO Quick QuoteHALO - Free Report) reported $492.97 million in revenue for the quarter ended September 2026, representing a year-over-year increase of 39.2%. EPS of $2.39 for the same period compares to $1.72 a year ago.

The reported revenue represents a surprise of +2.27% over the Zacks Consensus Estimate of $482.01 million. With the consensus EPS estimate being $2.29, the EPS surprise was +4.37%.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Halozyme Therapeutics performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Revenues- Product sales, net: $137.33 million versus $127.75 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +45.7% change.
• Revenues- Royalties: $341 million compared to the $327.97 million average estimate based on four analysts. The reported number represents a change of +44.5% year over year.
• Revenues- Revenues under collaboration agreements: $14.65 million versus the four-analyst average estimate of $26.3 million. The reported number represents a year-over-year change of -39%.

View all Key Company Metrics for Halozyme Therapeutics here>>>

Shares of Halozyme Therapeutics have returned +17.7% over the past month versus the Zacks S&P 500 composite's -0.4% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.